Understanding the Tip:
What are bracketing and matrixing:
Bracketing and matrixing are scientifically justified designs used to reduce the number of stability tests required when dealing with multiple strengths, fill volumes, or packaging sizes of a single product line.
Bracketing tests only the extremes (e.g., lowest and highest strengths), while matrixing staggers time point testing across batches or configurations. Both save time and resources without sacrificing scientific integrity.
Why these approaches matter:
In today’s cost-sensitive development environment, reducing redundant testing while maintaining compliance is a top priority. Bracketing and matrixing allow teams to gather meaningful data across variations efficiently.
These models are especially beneficial during scale-up, global submissions, or when launching multiple strengths with identical formulations.
Risks of improper use:
If not properly justified or documented, regulatory authorities may reject bracketing or matrixing designs. They must be grounded in sound scientific rationale and supported by historical data or formulation similarity.
Misapplication can lead to delayed approvals, extra testing requirements, or post-approval commitments.
Regulatory and Technical Context:
ICH guidance on reduced designs:
ICH Q1D provides the framework for applying bracketing and matrixing in stability studies. It outlines conditions under which these approaches are acceptable and how to statistically justify reduced testing models.
The guideline emphasizes that these designs must not compromise the ability to
Criteria for using bracketing:
Bracketing is ideal when products are identical in composition except for strength or fill volume. It assumes that stability of intermediate strengths will fall between the tested extremes.
This is commonly applied to tablets, capsules, or syrups where formulations are linear and excipient ratios are consistent.
Matrixing time points and batches:
Matrixing involves testing only a subset of samples at each time point, reducing workload while preserving data integrity. For example, three batches may be tested at staggered time points to cover all intervals collectively.
This approach is best suited when long-term trends are already well characterized or when resources are limited during early phases.
Best Practices and Implementation:
Design with clear scientific justification:
Use bracketing only when the product design justifies it—uniform packaging materials, identical manufacturing processes, and consistent formulation components. Provide a risk assessment explaining why intermediate strengths behave similarly.
Matrixing should be designed with balanced representation across batches and time points. Use statistical tools to validate coverage and minimize bias.
Document clearly in your stability protocol:
Include diagrams or tables showing which strengths or batches are being tested at which time points. Reference ICH Q1D and explain the logic behind your design choices.
Ensure that the approach is reviewed by QA and Regulatory Affairs before inclusion in submission documentation.
Monitor results and revert if necessary:
Continue trending data from bracketing and matrixing studies as it becomes available. If unexpected degradation is observed in an untested strength, conduct confirmatory testing immediately.
Stay prepared to expand testing if authorities question the validity of reduced models or if real-time performance diverges from projections.